Cagrilintide: The Amylin Analog in the GLP-1 Conversation

A different hormone than the GLP-1 drugs

Cagrilintide gets grouped with the GLP-1 research compounds because it shows up in the same metabolic trials, but mechanistically it sits on a separate branch. It is a long-acting amylin analog.

Amylin is a hormone co-secreted with insulin from the same pancreatic beta cells. It acts in the brainstem and hypothalamus on amylin and calcitonin receptors, and its role in research is tied to satiety, the rate of gastric emptying, and meal-ending signals, overlapping in *effect* with the incretin pathway but reaching it through different receptors. Native amylin is impractical to study directly because it aggregates and has a very short half-life; cagrilintide is an engineered analog built to be soluble and long-acting enough for once-weekly study.

Why it's usually studied alongside semaglutide

The central research question isn't really "what does cagrilintide do alone", it's "what does adding an amylin signal to a GLP-1 signal do that either does separately?" Two pathways converging on appetite and energy balance is a natural combination hypothesis, and that's where the most attention has gone.

What the research examined

A dose-finding phase 2 trial studied once-weekly cagrilintide on its own for weight management in people with overweight and obesity, reporting dose-dependent reductions in body weight, with gastrointestinal effects the most common adverse events (Lau et al., *Lancet* 2021). The combination question was taken up in a phase 2 trial co-administering cagrilintide with semaglutide in type 2 diabetes (Frías et al., *Lancet* 2023). These are findings from controlled research trials, not descriptions of any outcome outside a study.

Limitations and open questions

• Investigational. Cagrilintide is not an approved product; its long-term safety profile is still being established.
• The combination is the variable. Much of the interest is in cagrilintide-plus-semaglutide, which makes attributing effects to the amylin arm specifically an ongoing analytical question.
• Class-typical adverse events. As with the incretin compounds, gastrointestinal effects dominated the reported events.

Supplied lyophilized for laboratory research use only. Not for human consumption.

References

1. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. *Lancet.* 2021;398(10317):2160–2172. PubMed
2. Frías JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. *Lancet.* 2023;402(10403):720–730. PubMed